Sydney biotech targets niche vax market

By Megan Brodie 3 years ago | In Vaccines
  • 3 years ago
EnGenIC founders Drs Jennifer MacDiarmid and Himanshu Brahmbhatt

13 September 2021 A Sydney-based biotech developing a world-first nanocellular technology for hard-to-treat cancers has…

This is subscriber-only content. Please login to continue reading.